COAGHemab Therapeutics Holdings, Inc.
$31.60
$31.60
$24.9852 weeks$54.90
Price
End-of-day closes, not the intraday tick.
The five questions
2 of 5 availableOnly two of the five can be answered for COAG today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$1.29B
1 yearn/a
5 yearsn/a
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 10, 2026, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 24, 2026On September 24, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Hemab Therapeutics Holdings, Inc. (the “Company”), the Board elected Keli Walbert to serve as a member of the Board, effective immediately.Director or officer change · Form 8-K
- May 11, 2026On May 8, 2026, Laura Tadvalkar, Ph.D., notified Hemab Therapeutics Holdings, Inc. (the “Company”) of her decision to resign as a member of the Company’s board of directors (the “Board”), effective immediately.Director or officer change · Form 8-K
- May 4, 2026On May 4, 2026, the Company completed its IPO of 19,262,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,512,500 additional shares of common stock, at a public offering price of $18.00 per share.Charter/bylaw amendment or fiscal-year change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Biotechnology
The closest names by size in the same industry